Latest Insider Transactions at Biocryst Pharmaceuticals Inc (BCRX)
This section provides a real-time view of insider transactions for Biocryst Pharmaceuticals Inc (BCRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOCRYST PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOCRYST PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2022
|
Alane P Barnes Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+12.75%
|
-
|
|
Dec 15
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
14,100
-1.56%
|
$141,000
$10.9 P/Share
|
|
Dec 15
2022
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,175
-2.06%
|
$41,750
$10.88 P/Share
|
|
Dec 15
2022
|
Michael L Jones Exec. Director, Finance - PAO |
SELL
Open market or private sale
|
Direct |
445
-3.97%
|
$4,450
$10.9 P/Share
|
|
Dec 15
2022
|
Charles K Gayer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,100
-2.8%
|
$61,000
$10.9 P/Share
|
|
Dec 15
2022
|
Anthony Doyle Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,700
-3.36%
|
$57,000
$10.9 P/Share
|
|
Dec 15
2022
|
Helen M. Thackray Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
3,125
-2.29%
|
$31,250
$10.89 P/Share
|
|
Dec 02
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
82,656
-8.4%
|
$991,872
$12.8 P/Share
|
|
Dec 02
2022
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
82,656
+7.75%
|
$82,656
$1.42 P/Share
|
|
Dec 01
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
214,917
-19.24%
|
$2,793,921
$13.0 P/Share
|
|
Dec 01
2022
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
214,917
+16.14%
|
$214,917
$1.42 P/Share
|
|
Dec 01
2022
|
Michael L Jones Exec. Director, Finance - PAO |
SELL
Open market or private sale
|
Direct |
8,600
-43.44%
|
$111,800
$13.01 P/Share
|
|
Dec 01
2022
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,600
+30.28%
|
$8,600
$1.42 P/Share
|
|
Nov 30
2022
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
421
+1.34%
|
$5,473
$13.36 P/Share
|
|
Nov 30
2022
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,497
+1.51%
|
$19,461
$13.36 P/Share
|
|
Nov 30
2022
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
842
+4.54%
|
$10,946
$13.36 P/Share
|
|
Nov 30
2022
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
421
+1.33%
|
$5,473
$13.36 P/Share
|
|
Nov 14
2022
|
Yarlagadda S Babu Chief Discovery Officer |
SELL
Open market or private sale
|
Direct |
31,515
-9.55%
|
$409,695
$13.88 P/Share
|
|
Nov 14
2022
|
Yarlagadda S Babu Chief Discovery Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+14.15%
|
$100,000
$1.42 P/Share
|
|
Aug 31
2022
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
404
+1.3%
|
$5,252
$13.9 P/Share
|
|
Aug 31
2022
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
809
+4.58%
|
$10,517
$13.9 P/Share
|
|
Aug 31
2022
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,438
+1.47%
|
$18,694
$13.9 P/Share
|
|
Aug 31
2022
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
404
+1.3%
|
$5,252
$13.9 P/Share
|
|
Jun 07
2022
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+21.64%
|
-
|
|
Jun 07
2022
|
Steven K Galson Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+50.0%
|
-
|
|
Jun 07
2022
|
Kenneth B Lee Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+25.74%
|
-
|
|
Jun 07
2022
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+44.47%
|
-
|
|
Jun 07
2022
|
George B Abercrombie Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+50.0%
|
-
|
|
Jun 07
2022
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+29.86%
|
-
|
|
Jun 07
2022
|
Amy E Mc Kee Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+50.0%
|
-
|
|
Jun 07
2022
|
Nancy J Hutson Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+14.17%
|
-
|
|
Jun 07
2022
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+11.93%
|
-
|
|
Jun 07
2022
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+29.76%
|
-
|
|
Jun 07
2022
|
Machelle Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,866
+50.0%
|
-
|
|
May 31
2022
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,078
+2.47%
|
$18,702
$9.31 P/Share
|
|
May 31
2022
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,138
+26.25%
|
$10,242
$9.31 P/Share
|
|
May 31
2022
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,138
+6.15%
|
$10,242
$9.31 P/Share
|
|
May 31
2022
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
569
+1.66%
|
$5,121
$9.31 P/Share
|
|
Apr 18
2022
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$55,000
$11.04 P/Share
|
|
Apr 18
2022
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$15,000
$3.32 P/Share
|
|
Apr 01
2022
|
Helen M. Thackray Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
7,600
-5.28%
|
$121,600
$16.2 P/Share
|
|
Mar 10
2022
|
William P Sheridan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
161,139
-41.9%
|
$2,739,363
$17.26 P/Share
|
|
Mar 10
2022
|
William P Sheridan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
148,302
+42.69%
|
$444,906
$3.22 P/Share
|
|
Mar 07
2022
|
Yarlagadda S Babu Chief Discovery Officer |
SELL
Open market or private sale
|
Direct |
20,000
-8.0%
|
$340,000
$17.16 P/Share
|
|
Mar 01
2022
|
Michael L Jones Exec. Director, Finance - PAO |
SELL
Open market or private sale
|
Direct |
2,300
-17.04%
|
$39,100
$17.2 P/Share
|
|
Mar 01
2022
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,300
+14.56%
|
$9,200
$4.73 P/Share
|
|
Feb 28
2022
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
301
+0.9%
|
$4,816
$16.61 P/Share
|
|
Feb 28
2022
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
602
+3.58%
|
$9,632
$16.61 P/Share
|
|
Feb 28
2022
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,128
+1.39%
|
$18,048
$16.61 P/Share
|
|
Feb 28
2022
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
602
+22.62%
|
$9,632
$16.61 P/Share
|